Somewhat Favorable News Coverage Somewhat Unlikely to Impact Emergent Biosolutions (EBS) Share Price
Headlines about Emergent Biosolutions (NYSE:EBS) have been trending somewhat positive this week, according to Accern. The research firm identifies negative and positive media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Emergent Biosolutions earned a news sentiment score of 0.25 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 47.3389017424469 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Here are some of the news headlines that may have effected Accern’s analysis:
- Emergent Biosolutions, Inc. (EBS) Releases Quarterly Earnings Results, Beats Estimates By $0.32 EPS (americanbankingnews.com)
- Trading summary of Unusual Activity – Emergent BioSolutions Inc. (EBS) – Wall Street Morning (wallstreetmorning.com)
- Emergent (EBS) Q3 Earnings Beat Estimates, Guidance Raised – Nasdaq (nasdaq.com)
- Edited Transcript of EBS earnings conference call or presentation 2-Nov-17 9:00pm GMT (finance.yahoo.com)
Emergent Biosolutions (NYSE:EBS) traded up $2.97 during mid-day trading on Friday, reaching $43.03. The company had a trading volume of 1,630,000 shares, compared to its average volume of 243,066. Emergent Biosolutions has a 12-month low of $24.70 and a 12-month high of $44.86. The company has a current ratio of 6.99, a quick ratio of 6.02 and a debt-to-equity ratio of 0.40. The stock has a market cap of $1,773.35, a price-to-earnings ratio of 22.77, a P/E/G ratio of 1.32 and a beta of 1.22.
Emergent Biosolutions (NYSE:EBS) last posted its earnings results on Thursday, November 2nd. The biopharmaceutical company reported $0.73 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.41 by $0.32. Emergent Biosolutions had a return on equity of 14.50% and a net margin of 13.42%. The firm had revenue of $149.43 million for the quarter, compared to analyst estimates of $124.55 million. During the same quarter in the prior year, the company earned $0.56 EPS. Emergent Biosolutions’s revenue was up 4.6% on a year-over-year basis. analysts anticipate that Emergent Biosolutions will post 1.48 EPS for the current year.
A number of equities research analysts recently issued reports on the company. Wells Fargo & Company reaffirmed an “outperform” rating and issued a $43.00 target price (up previously from $41.00) on shares of Emergent Biosolutions in a research note on Saturday, September 30th. Zacks Investment Research lowered Emergent Biosolutions from a “buy” rating to a “hold” rating in a research note on Friday, August 11th. Finally, BidaskClub raised Emergent Biosolutions from a “hold” rating to a “buy” rating in a research note on Friday, August 25th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $45.00.
ILLEGAL ACTIVITY NOTICE: “Somewhat Favorable News Coverage Somewhat Unlikely to Impact Emergent Biosolutions (EBS) Share Price” was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another website, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this story can be viewed at https://www.watchlistnews.com/somewhat-favorable-news-coverage-somewhat-unlikely-to-impact-emergent-biosolutions-ebs-share-price/1679173.html.
In other Emergent Biosolutions news, Director Jerome M. Hauer sold 10,776 shares of the business’s stock in a transaction on Tuesday, August 15th. The stock was sold at an average price of $35.83, for a total value of $386,104.08. Following the completion of the transaction, the director now directly owns 29,421 shares in the company, valued at approximately $1,054,154.43. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Daniel Abdun-Nabi sold 15,000 shares of the business’s stock in a transaction on Thursday, August 31st. The shares were sold at an average price of $37.21, for a total value of $558,150.00. Following the completion of the transaction, the chief executive officer now owns 219,134 shares of the company’s stock, valued at $8,153,976.14. The disclosure for this sale can be found here. Insiders sold a total of 180,227 shares of company stock valued at $6,993,970 over the last quarter. 16.50% of the stock is currently owned by insiders.
About Emergent Biosolutions
Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).
Receive News & Ratings for Emergent Biosolutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.